Level D· Scientific groundwork from lab and animal studiesNarrative ReviewPubMed

Restoring neuroplasticity after CNS trauma: cell therapy approaches in spinal cord and traumatic brain injury.

Palha AT., Lima MF., Carvalho M., Campos J., Sampaio-Marques B., Salgado AJ.

Narrative Review on Spinal Cord Injury, published in J Transl Med (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
J Transl Med (2026)
Country
England
Reported sample size
—
Source database
PubMed
PMID
42286677
DOI
10.1186/s12967-026-07933-5

Abstract (original English)

Background The central nervous system (CNS) has a limited regenerative capacity, rendering traumatic injuries such as spinal cord injury (SCI) and traumatic brain injury (TBI) highly disabling and difficult to treat. These insults trigger complex pathophysiological cascades, including extensive cell death, sustained inflammation, and the formation of a hostile inhibitory microenvironment that compromises neural plasticity and hampers tissue regeneration. The multifactorial nature of these mechanisms, together with a fragmented understanding of CNS plasticity, has hindered the development of effective therapeutic interventions. Main body In recent years, cell-based therapies have emerged as promising strategies to support neural repair and induce pro-regenerative processes. This approach encompasses multiple cell types, including bone marrow-derived mesenchymal stem cells (BMSCs), adipose-derived stem cells (ASCs), umbilical cord mesenchymal stem cells (UCMSCs), as well as neural progenitor cells (NPCs) and olfactory ensheathing cells (OECs). Clinical studies in SCI have reported functional improvements, particularly following treatment with BMSCs and peripheral blood-derived stem cells, although substantial methodological heterogeneity limits definitive conclusions. In TBI, clinical evidence remains more limited; however, preclinical studies consistently demonstrate the neuropr

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research